 |
LEHI, Utah, Sept. 4, 2025 /PRNewswire/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Jared Bearss, Chief Operating Officer of Halia, will provide a business overview presentation on Tuesday, September 9, 2025 at 7:00 am ET.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biopharmaceutical company focused on treating the root causes of inflammation. Leveraging genetic insights and AI-enabled discovery, Halia is building a robust pipeline of novel therapeutics based on genetic resilience that targets inflammatory pathways in diseases ranging from metabolic disorders to neurodegeneration and hematologic malignancies.
Halia’s mission is to create data-driven therapies that not only extend life but also improve its quality. The company is headquartered in Lehi, Utah, and is actively advancing global partnerships in clinical research, drug discovery, and personalized medicine.
To learn more, visit www.haliatx.com or follow us on LinkedIn and Twitter @HaliaTx.
Media Contact
Taylor Avei
Director of Business Development
Halia Therapeutics
[email protected]
Investor Contact
Leigh Salvo
New Street Investor Relations
[email protected]
ข่าวที่เกี่ยวข้อง
- JOYEE N01 Rolls Off Global Production Line as First Batch Delivery Ceremony for 2,000 Overseas Orders Takes Place
- GHA มอบการรับรองระดับ Distinction แก่ The Second Affiliated Hospital Zhejiang University School of Medicine เพื่อยกย่องความเป็นเลิศด้านประสบการณ์ผู้ป่วยในการเดินทางเข้ารับบริการทางการแพทย์ระหว่างประเทศ
- ต้นสนคริสต์มาสสูง 55 ฟุตประดับไฟสว่างไสวทั่วโตรอนโต เมื่อ The Distillery Winter Village ซึ่งสนับสนุนโดย Quince เปิดฉากต้อนรับปี 2026
- Cambodia Takes Bakong Global, Connecting ASEAN with Japan and Africa
